Q-omics provides the consensus-scored GPR19 profile across patient tissues and cancer cell-line models. GPR19 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GPR19 is differentially expressed in 17, with the highest sampling consensus in LUAD. Additionally, GPR19 RNA expression shows 18,369 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRP, LUAD, and DLBC as cancer lineages where GPR19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR19 survival associations across molecular data types. GPR19 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR19 RNA expression–survival associations across cancer types. High GPR19 expression shows unfavorable associations in KIRP, UVM, ACC, UCEC, LIHC and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GPR19 RNA expression.
This table summarizes GPR19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR19 shows higher tumor expression in LUAD, COAD, KIRC, BLCA, HNSC and THCA. The LUAD box plot shows higher GPR19 RNA expression in tumor versus normal tissue (log2 FC = +1.403, t-test p < 0.001).
This table shows molecular features associated with GPR19 in patient tissues and cancer cell lines. In patient samples, GPR19 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
